Certara Announces New Release of PK Submit
PRINCETON, N.J.— 2022 年 10 月 12 日 – Certara, Inc., a global leader in drug development software,…
Certara2022 年 10 月 12 日
How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing
Historically, the dosing strategy for oncology drugs focused on the maximum tolerated dose. This has…
Certara2022 年 10 月 5 日
Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist
Choosing the right technology and services vendor to support your organization’s transparency and disclosure (T&D)…
Certara2022 年 10 月 4 日
5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results
For the first time, the European Medicines Agency (EMA) has passed new regulations to help…
Certara2022 年 9 月 27 日
EU-CTR Challenges Drug Developers Faced in the First 6 Months
Under European Union Clinical Trial Regulation 536/2014 (EU-CTR), replacing the EU Clinical Trial Directive (Directive…
Certara2022 年 9 月 26 日
Optimize drug development with public data and predictive models – model-based meta-analysis (MBMA)
Properly understanding the probability of successful drug development requires utilization of all available information. Critical…
Certara2022 年 9 月 23 日
3 Takeaways from the FDA Oligo Guidance You Need to Know
In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…
Certara2022 年 9 月 23 日
Pinnacle 21 Data Exchange: Transforming External Vendor Data Management
The volume and complexity of clinical data are growing at a faster pace than the…
Certara2022 年 9 月 19 日
